Pelin Özcan KARA, Zehra Pınar KOÇ, Emel CEYLAN GÜNAY, Zeynep SELCAN SAĞLAM, Gökçe YAVAN

The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients

Imaging plays an important role in the evaluation of prostate cancer patients. In recent years, much attention has been focused on 68Ga-PSMA PET-CT in prostate cancer patients and has been widely used for staging, especially biochemical relapse-restaging and therapy response for these patients. The aim of this study was to evaluate 68 Ga PSMA PET-CT imaging in initial staging-first line imaging of prostate cancer from low to high risk patients based on standard reporting system with E PSMA molecular staging.

Keywords:

E-PSMA, PET-CT, Prostate cancer, PSMA PET,

Tam Metin

___

P Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., & Lawrentschuk, N. (2016). Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. European urology, 70(6), 926–937. https://doi.org/10.1016/j.eururo.2016.06.021
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., Matveev, V. B., Moldovan, P. C., van den Bergh, R. C. N., Van den Broeck, T., van der Poel, H. G., van der Kwast, T. H., Rouvière, O., Schoots, I. G., … Cornford, P. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European urology, 71(4), 618–629. https://doi.org/10.1016/j.eururo.2016.08.003
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., Mottet, N., & European Association of Urology (2014). EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. European urology, 65(1), 124–137. https://doi.org/10.1016/j.eururo.2013.09.046
Maurer, T., Gschwend, J. E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., Wester, H. J., Heck, M., Kübler, H., Beer, A. J., Schwaiger, M., & Eiber, M. (2016). Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. The Journal of urology, 195(5), 1436–1443. https://doi.org/10.1016/j.juro.2015.12.025 Dewes, S., Schiller, K., Sauter, K., Eiber, M., Maurer, T., Schwaiger, M., Gschwend, J. E., Combs, S. E., & Habl, G. (2016). Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiation oncology (London, England), 11, 73. https://doi.org/10.1186/s13014-016-0646-2
Shakespeare T. P. (2015). Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists. Radiation oncology (London, England), 10, 233. https://doi.org/10.1186/s13014-015-0548-8
Roach, P. J., Francis, R., Emmett, L., Hsiao, E., Kneebone, A., Hruby, G., Eade, T., Nguyen, Q. A., Thompson, B. D., Cusick, T., McCarthy, M., Tang, C., Ho, B., Stricker, P. D., & Scott, A. M. (2018). The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 59(1), 82–88. https://doi.org/10.2967/jnumed.117.197160
Fendler, W. P., Schmidt, D. F., Wenter, V., Thierfelder, K. M., Zach, C., Stief, C., Bartenstein, P., Kirchner, T., Gildehaus, F. J., Gratzke, C., & Faber, C. (2016). 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 57(11), 1720–1725. https://doi.org/10.2967/jnumed.116.172627.
Kuten, J., Mabjeesh, N. J., Lerman, H., Levine, C., Barnes, S., & Even-Sapir, E. (2019). Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer. The Israel Medical Association journal : IMAJ, 21(2), 100–104.
Ceci, F., Oprea-Lager, D. E., Emmett, L., Adam, J. A., Bomanji, J., Czernin, J., Eiber, M., Haberkorn, U., Hofman, M. S., Hope, T. A., Kumar, R., Rowe, S. P., Schwarzenboeck, S. M., Fanti, S., & Herrmann, K. (2021). E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European journal of nuclear medicine and molecular imaging, 48(5), 1626–1638. https://doi.org/10.1007/s00259-021-05245-y
Pfob, C. H., Ziegler, S., Graner, F. P., Köhner, M., Schachoff, S., Blechert, B., Wester, H. J., Scheidhauer, K., Schwaiger, M., Maurer, T., & Eiber, M. (2016). Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. European journal of nuclear medicine and molecular imaging, 43(11), 1962–1970. https://doi.org/10.1007/s00259-016-3424-3
Eiber, M., Herrmann, K., Calais, J., Hadaschik, B., Giesel, F. L., Hartenbach, M., Hope, T., Reiter, R., Maurer, T., Weber, W. A., & Fendler, W. P. (2018). Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 59(3), 469–478. https://doi.org/10.2967/jnumed.117.198119
Sweat, S. D., Pacelli, A., Murphy, G. P., & Bostwick, D. G. (1998). Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology, 52(4), 637–640. https://doi.org/10.1016/s0090-4295(98)00278-7

___

Bibtex	@olgu sunumu { moi1339181, journal = {Molecular Oncologic Imaging}, eissn = {2791-965X}, address = {Mersin Üniversitesi Çiftlikköy Kampüsü Tıp Fakültesi}, publisher = {Mersin Üniversitesi}, year = {2023}, volume = {3}, number = {2}, pages = {17 - 24}, title = {The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients}, key = {cite}, author = {Kara, Pelin Özcan and Koç, Zehra Pınar and Ceylan Günay, Emel and Selcan Sağlam, Zeynep and Yavan, Gökçe} }
APA	Kara, P. Ö. , Koç, Z. P. , Ceylan Günay, E. , Selcan Sağlam, Z. & Yavan, G. (2023). The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients . Molecular Oncologic Imaging , 3 (2) , 17-24 .
MLA	Kara, P. Ö. , Koç, Z. P. , Ceylan Günay, E. , Selcan Sağlam, Z. , Yavan, G. "The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients" . Molecular Oncologic Imaging 3 (2023 ): 17-24 <
Chicago	Kara, P. Ö. , Koç, Z. P. , Ceylan Günay, E. , Selcan Sağlam, Z. , Yavan, G. "The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients". Molecular Oncologic Imaging 3 (2023 ): 17-24
RIS	TY - JOUR T1 - The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients AU - Pelin ÖzcanKara, Zehra PınarKoç, EmelCeylan Günay, ZeynepSelcan Sağlam, GökçeYavan Y1 - 2023 PY - 2023 N1 - DO - T2 - Molecular Oncologic Imaging JF - Journal JO - JOR SP - 17 EP - 24 VL - 3 IS - 2 SN - -2791-965X M3 - UR - Y2 - 2023 ER -
EndNote	%0 Molecular Oncologic Imaging The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients %A Pelin Özcan Kara , Zehra Pınar Koç , Emel Ceylan Günay , Zeynep Selcan Sağlam , Gökçe Yavan %T The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients %D 2023 %J Molecular Oncologic Imaging %P -2791-965X %V 3 %N 2 %R %U
ISNAD	Kara, Pelin Özcan , Koç, Zehra Pınar , Ceylan Günay, Emel , Selcan Sağlam, Zeynep , Yavan, Gökçe . "The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients". Molecular Oncologic Imaging 3 / 2 (Eylül 2023): 17-24 .
AMA	Kara P. Ö. , Koç Z. P. , Ceylan Günay E. , Selcan Sağlam Z. , Yavan G. The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients. Molecular Oncologic Imaging. 2023; 3(2): 17-24.
Vancouver	Kara P. Ö. , Koç Z. P. , Ceylan Günay E. , Selcan Sağlam Z. , Yavan G. The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients. Molecular Oncologic Imaging. 2023; 3(2): 17-24.
IEEE	P. Ö. Kara , Z. P. Koç , E. Ceylan Günay , Z. Selcan Sağlam ve G. Yavan , "The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients", , c. 3, sayı. 2, ss. 17-24, Eyl. 2023